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By Susan I. Finkelstein
A couple of unpacked cardboard boxes
placed neatly atop a filing cabinet are the only
indication that Gustavo Aguirre,V’68, GR’75,
professor of medical genetics and ophthalmol-
ogy, returned to the Ryan Hospital just this July,
after a 12-year stint at Cornell. Other than the
boxes, the second-floor office appears never to
have been inhabited by anyone else: framed
covers of journals featuring Dr. Aguirre’s work
adorn the walls, as do as artistic renderings of
eyes in various abstract states, a needlepoint
wall-hanging of dog faces, and other assorted
pieces. One of the country’s foremost veteri-
nary ophthalmological and gene-therapy
researchers, Dr. Aguirre—earning his V.M.D.
and Ph.D. at Penn, and serving on the faculty
here for over 20 years—has truly come home.
Dr. Aguirre’s research focuses on inherited
diseases of the eye, especially degeneration of
the retina in dogs, humans, and other mam-
mals. In 2001, he, his colleagues at Cornell’s
James A. Baker Institute for Animal Health, and
researchers at Penn were the first to restore
vision in blind dogs using gene therapy:
“Lancelot,” a four-year-old briard mix blind
since birth, was the first creature ever to recover
sight thanks to this revolutionary work, which
also holds
promise for
curing a similar
disease in chil-
dren, Leber
congenital
amaurosis. In
gratitude,
Lancelot has appeared before Congress with the
Aguirre team for their testimony on the impor-
tance of increased funding for eye research to
advance gene therapy—cer-
tainly an unusual lobbyist!
In the experiments
involving Lancelot and
three of his littermates, Dr.
Aguirre and his colleagues
injected a virus carrying a
healthy copy of the defec-
tive gene into a part of the
retina containing light-
sensing cells. The virus
“infected” those cells,
releasing the normal gene
material. Within three to
four weeks, cells with the
healthy copy began to pro-
duce vitamin A that, together with opsin,
formed the visual pigment rhodopsin, eventu-
ally allowed the dogs to see for the first time in
their lives. Work, however, remains to be done
in developing and testing gene therapy applica-
tions in dogs with other congenital disorders—
and, more importantly, in people.“Regardless
of how successful the treatment has been for
dogs, it is essential that more studies are carried
out to establish the long-term safety and effica-
cy of gene therapy for human patients,” Dr.
Aguirre notes.
Currently, Dr. Aguirre is involved in research
regarding a hereditary, blinding disorder of the
retina called progressive retinal atrophy, or PRA
as it is commonly known. This disease was first
recognized in Gordon setters in Europe in the
early twentieth century, but PRA has since been
identified in many breeds. In human families,
the diseases equivalent to PRA in dogs are
termed retinitis pigmentosa.
Siberian huskies and Samoyeds have a
unique type of PRA called X-linked PRA, since
it is transmitted through the X chromosome of
the mother. X-linked PRA is the “most com-
mon severe, inherited disease of the retina,” says
Dr. Aguirre, who has identified the genetic
defect that causes the disease. The test that
detects the mutation will allow breeders of
huskies and Samoyeds—and eventually other
breeds as well—to prevent X-linked PRA in
their lines by recognizing the carrier females.
Significantly, since dogs and people share such
similar genetic makeups, the research has the
potential to identify the causes of some cases of
X-linked blindness in humans.
Given the growing attention garnered by
gene therapy and the entirely new methods of
treating disease it is generat-
ing, the return of Gus
Aguirre to Penn has been
quite a coup for the School.
And the benefits are mutual:
“It was great coming back to
Philadelphia; my family still
lives in the area,” says Dr.
Aguirre—in fact, one of his
sons, Dr. Geoffrey Aguirre,
GR’98, M’00, is an assistant
professor in the Center for
Cognitive Neuroscience at
Penn Medicine. The two
Aguirres are collaborating
on a project studying the
brains of dogs before and after gene therapy
restored their vision.
Now, if only those last parts for Dr. Aguirre’s
fluorescent microscope would arrive….
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Class of 2008 Profile
The Class of 2008 arrived on campus for
orientation at the end of August. Eighty-
seven women and 21 men, ranging in age
from 21 to 48 years, with a mean GPA of
3.54, are already hard at work, coping with
the heavy courseload. The majority of the
students, 64 percent, are from Pennsylvania,
the balance are from New Jersey (8), Mass-
achusetts (7), New York (5), Connecticut,
Illinois and Virginia (3 each), international
(2, Bermuda and Japan), and one each from
Colorado, District of Columbia, Kentucky,
Maine, Maryland, and Oregon. The School
received 1,217 applications and made offers
to 154 applicants.
The majority of the students’ under-
graduate degrees is a BS (64); a BA was
earned by 43 and BFA by one. Five students
have an MS, two an MA, and one an MLAS.
Eight students received their undergraduate
degrees from Penn and Cornell. In all, 62
undergraduate schools are represented in
this class with 35.2 percent of the students
having attended top-tier (most competi-
tive) schools, 24.1 percent second-tier
(highly competitive) schools, and 21.3 per-
cent third-tier (very competitive) schools.
Promotions and appointments 
Effective July 1, a number of faculty
members were promoted:
Dr. Charles H.Vite to assistant professor
of neurology; Dr. Anna S. Kashina to assistant
professor of biochemistry; Dr. Amy Kapatkin
to associate professor of surgery; Dr. Karen
L. Rosenthal to assistant professor of special
species medicine and surgery; Dr. Gabriela
S. Seiler to assistant professor of radiology;
Chick Weisse,V’98, to assistant professor of
surgery; Dr. Wilfried Mai to assistant profes-
sor of radiology; Dr. Andras Komaromy to
assistant professor of ophthalmology; Drs.
Danian Gu, Petra Werner, and Barbara
Zangerl to research assistant professors of
medical genetics; and Dr. Robert Poppenga
to professor of toxicology.
Lancelot, the Briard mix whose
sight was restored.
